Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Mar 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs INCB 123667 (Primary) ; Antineoplastics; Bevacizumab; Fulvestrant; Olaparib; Paclitaxel; Palbociclib; Ribociclib
  • Indications Advanced breast cancer; Carcinoma; Endometrial cancer; Fallopian tube cancer; Gastric cancer; Gastrointestinal cancer; Gynaecological cancer; HER2 negative breast cancer; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Solid tumours; Triple negative breast cancer; Uterine cancer
  • Focus Adverse reactions
  • Sponsors Incyte Corporation

    • Most Recent Events

    • 27 Dec 2024 Protocol has been amended to include 14 new arms, changed from 7 to 21.
    • 27 Dec 2024 Planned number of patients changed from 340 to 640.
    • 27 Dec 2024 Planned primary completion date changed from 27 Apr 2024 to 29 Aug 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top